Market closed · Next open: Monday 9:30 AM ET
Last update: Nov 20, 2026, 6:14 PM ET
Globus Medical, Inc.
▼ 12.8% on Nov 6, 2026

Why Globus Medical, Inc. (GMED) Stock Fell 12.8% on Nov 6, 2026

Researched by BestStocks Market Desk · Published Nov 6, 2026
Prior close
$81.44
Nov 6, 2026 close
$71.05
Change
−$10.39
-12.76%
Rel. volume
6.3×
9.3M shares

What happened

Valuation-12.8%high confidence

Globus Medical reported Q3 2026 net sales of $763.7 million, missing consensus estimates (~$792–$793 million) and declining 0.7% year-over-year, while management cut full-year 2026 revenue guidance from $3.18–$3.22 billion to $3.09 billion (investing.com). The selloff was compounded by a 25.7% drop in Nevro sales, slower sales rep productivity, and delayed spine product launches now pushed to 2027, plus BMO Capital Markets downgrading GMED from Outperform to Market Perform with a price target cut from $94 to $78. Stock fell 11.15% to $72.36 on elevated volume of 5.1 million shares (6.08x historical average for this time of session).

Source: fmp_intraday
What to watch next

Q4 2026 results and updated 2027 guidance (consensus EPS $1.33 expected at next earnings, scheduled for 2027-02-23); Nevro sales stabilization and spine product launch execution in early 2027.

Other developments that session

News

Globus Medical cuts 2026 revenue guidance due to spine launch delays and Nevro sales weakness.

Source: Zacks

Frequently asked questions

Why did Globus Medical, Inc. (GMED) stock fall on Nov 6, 2026?

Globus Medical reported Q3 2026 net sales of $763.7 million, missing consensus estimates (~$792–$793 million) and declining 0.7% year-over-year, while management cut full-year 2026 revenue guidance from $3.18–$3.22 billion to $3.09 billion (investing.com). The selloff was compounded by a 25.7% drop in Nevro sales, slower sales rep productivity, and delayed spine product launches now pushed to 2027, plus BMO Capital Markets downgrading GMED from Outperform to Market Perform with a price target cut from $94 to $78. Stock fell 11.15% to $72.36 on elevated volume of 5.1 million shares (6.08x historical average for this time of session).

How much did GMED stock fall on Nov 6, 2026?

GMED fell 12.8% during the Nov 6, 2026 trading session.

This is an archived analysis of GMED's Nov 6, 2026 session.
See GMED's latest changes →
Educational research tool — not personalized investment advice. Figures reflect the Nov 6, 2026 session as first analyzed.